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Normothermic Perfusion in the Assessment and
Preservation of Declined Livers Before
Transplantation: Hyperoxia and
Vasoplegia—Important Lessons From the First
12 Cases
Christopher J.E. Watson, MD,1,2 Vasilis Kosmoliaptsis, PhD,1,2 Lucy V. Randle,1,2 Alexander E. Gimson, MD,3
Rebecca Brais, BA BM,4 John R. Klinck, MD,5 Mazin Hamed, MRCS,1,2 Anastasia Tsyben, MB BChir,6
and Andrew J. Butler, MB, MChir1,2
Background. A program of normothermic ex situ liver perfusion (NESLiP) was developed to facilitate better assessment and
use of marginal livers, while minimizing cold ischemia.Methods. Declined marginal livers and those offered for research were
evaluated. Normothermic ex situ liver perfusion was performed using an erythrocyte-based perfusate. Viability was assessed with
reference to biochemical changes in the perfusate. Results. Twelve livers (9 donation after circulatory death [DCD] and 3 from
brain-dead donors), median Donor Risk Index 2.15, were subjected toNESLiP for amedian 284minutes (range, 122-530minutes)
after an initial cold storage period of 427 minutes (range, 222-877 minutes). The first 6 livers were perfused at high perfusate
oxygen tensions, and the subsequent 6 at near-physiologic oxygen tensions. After transplantation, 5 of the first 6 recipients
developed postreperfusion syndrome and 4 had sustained vasoplegia; 1 recipient experienced primary nonfunction in conjunction
with a difficult explant. The subsequent 6 liver transplants, with livers perfused at lower oxygen tensions, reperfused uneventfully.
Three DCD liver recipients developed cholangiopathy, and this was associated with an inability to produce an alkali bile
during NESLiP. Conclusions. Normothermic ex situ liver perfusion enabled assessment and transplantation of 12 livers that
may otherwise not have been used. Avoidance of hyperoxia during perfusion may prevent postreperfusion syndrome and
vasoplegia, and monitoring biliary pH, rather than absolute bile production, may be important in determining the likelihood of
posttransplant cholangiopathy. Normothermic ex situ liver perfusion has the potential to increase liver utilization, but more work
is required to define factors predicting good outcomes.
(Transplantation 2017;101: 1084–1098)
The last decade has seen increasing numbers of patientsbeing listed for liver transplantation but a decline in the overall quality of available donor organs, with largernumbers of older donors, donors dying from hypoxic brain
injury, and after circulatory death (DCD).1 As a consequence
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deceased donors were not transplanted in spite of over
3000 potential recipients dying or being removed from the
waiting list in the same year.1 The situation is similar in the
United Kingdom, where 19% of patients either die or are re-
moved from the waiting list within 2 years of listing, whereas
8% of livers recovered from donation after brain death
(DBD) donors, and 26% of livers recovered from DCD
donors were not transplanted.2,3
The principal reason for discard of a liver that has been
recovered for transplantation is fear that the liver will not
provide life-sustaining function after transplantation, usually
in the setting of steatosis, prolonged warm ischemia, adverse
hemodynamic characteristics during the DCD withdrawal
phase, or prolonged cold ischemia.4 Although the liver may
have functioned well in the donor, warm and cold ischemia
impose an unpredictable injury on the liver thatmaymanifest
only after reperfusion in the recipient.
In an effort to increase the utilization of livers, the United
Kingdom introduced a “fast-track liver offer scheme” in
1997 to place livers “that have been declined for any reason,
or have yet to be accepted, at or after cross-clamp” in the
donor.5 A simultaneous offer is made to every UK center that
has not previously declined the liver. Such livers are typically
reported to be abnormal (eg, steatotic, poor in situ perfusion)
or were associated with a long withdrawal phase. Because
fast-track offering usually takes place after organ recovery,
such livers are usually associated with long cold ischemic
times. Livers not accepted on the fast-track schememay be al-
located for research if there is appropriate consent. In the pe-
riod of this report, 587 livers were fast-tracked, with 11%
being transplanted.
The ability to undertake normothermic ex situmachine per-
fusion of livers (NESLiP) has introduced a new dimension to
the assessment of donor livers before implantation and enables
cold ischemia to be halted while a recipient is prepared for
transplantation. Although an initial clinical study has shown
encouraging results fromnormothermic preservation through-
out the period of extracorporeal storage,6 there are few reports
of the use ofNESLiP in the assessment ofmarginal liver grafts.7
Against the background of increasingly marginal liver of-
fers, we established a clinical program of NESLiP in our cen-
ter, targeting livers that were considered potentially viable,
but where the ischemic time would be unreasonably long or
there was uncertainty about the liver based on the subjective
opinion of the retrieving surgeon. The program was paused
after 6 cases due to adverse events, and after further investi-
gation and subsequent reduction in the level of oxygenation
during perfusion, was restarted. This paper describes our
initial experience of 12 cases, and the lessons learned that
we believe will benefit all investigators in this area.
MATERIALS AND METHODS
Livers and Recipients
Routine national and zonal liver offers, as well as those of-
fered through the UK fast-track liver offering scheme, were
considered. Livers that had been offered directly for research
were also considered. Normothermic ex situ liver perfusion
was typically considered where there was uncertainty about
the liver such that the recipient hepatectomy could not start be-
fore visualizing the liver, and the prolongation of cold ischemic
time that this imposed would have deleterious consequences
on the liver. Livers were offered to the highest priority patient
(by biochemical or clinical criteria) of suitable size and blood
group match who had previously consented for a liver of that
type and separately consented for it to undergo NESLiP.
Preparation
Livers were prepared for transplantation in a standard
manner. In addition, a 6Fr infant feeding tube was placed
into the bile duct to drain bile, and the cystic duct was ligated
in continuity. Infusion cannulae were tied into the portal vein
(PV) and celiac trunk (HA). In the last 6 livers, a 6Fr catheter
was also suturedwith its tip in the right hepatic vein for direct
sampling of venous effluent. The liver was flushedwith either
a litre of succinylated gelatin (Gelofusine, BBraunMedical, UK)
(cases 1 to 6) or with compound sodium lactate (Hartmann
solution, Baxter, UK) (cases 7 to 12) at room temperature
before NESLiP (Figure 1). Flushing was performed to remove
residual UW solution, in particular its potassium. Hartmann
solution was used in the last 6 cases to provide lactate as
a substrate to enhance monitoring of its clearance during
perfusion (1 L contains 29 mmol lactate).
Just before explanting the recipient’s diseased liver, NESLiP
was stopped and the donor liver flushed with 2-L ice-cold UW
solution (Belzer-UW, Bridge to Life, London, UK). Implanta-
tion involved a caval-preserving cavo-cavostomy anastomosis.
The liver was flushed with a litre of succinylated gelatin at
room temperature before reperfusion via the PV; arterial reper-
fusion followed portal reperfusion.
FIGURE 1. Changes in protocol for normothermic ex situ liver perfusion. Comparison of the protocols for flushing and perfusing the first and
last 6 livers undergoing NESLiP.
© 2017 Wolters Kluwer Watson et al 1085
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Perfusion Method
Normothermic ex situ liver perfusion was performed using
aLiverAssist device (OrganAssist,Groningen, theNetherlands),
which provides pressure-regulated flow from 2 independent
pumps and oxygenators supplying PVand hepatic artery, respec-
tively. The perfusate comprised 3 units of leucocyte-depleted
washed red cells which had a variable volume of around 1 L.
The red cells were added to a liter of either succinylated gelatin
or Steen solution (Xvivo Perfusion, Göteborg, Sweden) (cases 6
to 8 only) and supplementedwith 30mmol sodiumbicarbonate,
25 000 units (50 mg) heparin, antibiotics, calcium chloride,
magnesium sulphate, and amino acids (Aminoven-25, Fresenius
Kabi Ltd, UK). The final hemoglobin concentrationwas amedian
6.1 g/dL (range, 5.1-7.4); hematocrit, 0.18 (range, 0.16-0.22).
Epoprostenol 2 μg/hwas given by infusion, and insulin was given
either as an infusion or bolus. Bile salts were not administered.
In the first 6 perfusions, the oxygenators were supplied with
an oxygen/CO2 mixture, the proportion of CO2 being varied
according to arterial pH and pCO2 (Figure 1). In the last
6 cases, air (21% O2) replaced pure O2 as the principle gas
supplied to the oxygenators with an intention of achieving
an hepatic venous oxygen saturation between 55% and 75%.
The gas flow was divided between both portal and arterial
oxygenators by a Y-connector. Arterial pO2 was around
20 kPa (153 mm Hg), with 98% to 99% oxygen saturations
and 65% to 85% saturation of portal blood, the difference
FIGURE 2. Storage times of the 12 livers, broken down by periods of storage. Horizontal bars represent individual livers, showing the periods
from withdrawal of treatment, asystole, cold storage, and normothermic perfusion, removal from the machine and being cold flushed during
implantation, up to reperfusion in the recipient.
FIGURE 3. Perfusate glucose concentration during normothermic ex situ liver perfusions. Individual lines represent the change in perfusate
glucose for each liver in the series; blue lines with open symbols represent livers perfused with low oxygen tensions. With 3 exceptions, there
was a release of glucose on reperfusion of the liver followed by a slow fall towards normal. Note the glucose in livers 3, 6, and 10 were in the
“normal” range initially. Case 10 received an infusion of glucose between 4 and 6 hours, after which there was a spontaneous and rapid fall.
© 2017 Wolters Kluwer Watson et al 1087
being explained by the greater flow rate of perfusate across the
portal oxygenator than arterial oxygenator, hence less gas
uptake. Supplementary oxygen was required in 3 cases at the
start of NESLiP. Bicarbonate was given if the perfusate pH is
less than 7.2.
Normothermic ex situ liver perfusion was commenced at
20°C, and the circuit warmed to 37°C over 20 to 30 minutes;
As the perfusion temperature increased, the HA and PV pres-
sures were increased from30 and 4 to 60 and 9mmHg, respec-
tively. Perfusate gas estimations were performed every 20 to
30 minutes; hemoglobin, potassium, sodium, glucose, and
lactate concentrations were also measured. Samples were ini-
tially only taken from the arterial inflow, but in the last 6 perfu-
sions, hepatic vein gas estimations were also done. Arterial and
PV flows were monitored throughout, as was bile production.
Perfusate cultures were taken from each case andwere negative.
Viability
Viability was judged by assessing changes in lactate, glu-
cose, and transaminase concentrations as well as on the ability
of the liver tomaintain pHwithout supplemental bicarbonate.
FIGURE 4. Perfusate lactate concentration during normothermic ex situ liver perfusion. Lactate concentrations for each liver in the series. Note
the spontaneous fall in all cases. The livers in the last 6 caseswere flushedwith compound sodium lactate (Hartmann solution) before perfusion,
washing out potassium and loading the liver with lactate to enable more ready assessment of a fall. Cases 5 and 9 were livers that had suffered
a degree of parenchymal trauma; the delayed lactate fall in 9 and incomplete fall in 5 were interpreted in that light, with presumed ongoing lac-
tate production in the damaged segments. Case 6, the slowest fall, suffered primary non function.
FIGURE 5. Perfusate ALT during normothermic ex situ liver perfusion. Perfusate ALTs for each liver during perfusion. Case 6 suffered primary
nonfunction, and case 8 was a steatotic liver.
1088 Transplantation ■ May 2017 ■ Volume 101 ■ Number 5 www.transplantjournal.com
Definitions
Postreperfusion syndrome was defined as a fall in mean arte-
rial pressure (MAP)within 5minutes of reperfusion in the recip-
ient to less than 70% of the baseline value in the last 5 minutes
of the anhepatic period.8 In the absence of an accepted defini-
tion,9-11 we defined vasoplegia as a fall in MAP on reperfusion
to less than 50 mmHg either sustained longer than 30 minutes
and/or requiring greater than 0.15 μg/kg per minute norepi-
nephrine, greater than 2U/h argipressin, or infusion of epineph-
rine (ie, significant hypotension resistant to pressors).
Evidence of Damage From Reactive Oxygen
Species (ROS)
To seek evidence that the perfusion technique used in the
first 6 livers was associated with damage from reactive oxygen
species, 10 livers not used for transplantation were examined.
Five of the livers had previously been perfused at high arterial
pO2, and 5 were perfused to evaluate low oxygen tensions
using air; this was used for the subsequent 6 transplants. Esti-
mations of liver protein carbonyl concentrations and perfusate
syndecan concentrations were measured as markers of ROS
damage. The methods and results are in the SDC, http://
links.lww.com/TP/B394.
Institutional Review
Perfusion of discarded livers was approved by a research
ethics committee, and the transplantation of perfused livers
was approved by our institution’s New Interventional Proce-
dures Committee. All patients gave informed consent. Where
appropriate, the recipients separately consented to receive
higher risk organs, such as DCD livers, according to our
standard practice.
Contemporaneous Cohort for Comparison
To provide comparative data, a contemporaneous cohort of
24 liver recipients were identified including all other fast-track
recipients in the study period along with livers transplanted
immediately before and after each NESLiP case of similar
type (DBD/DCD).
RESULTS
Livers
Twelve livers underwent NESLiP over a 15-month period.
Nine had been turned down by other centers, including 3 that
were fast-track offers; 2 had been declined by all UK centers
and were offered for research (cases 9 and 10), and 1 had a
prolonged ischemic time due to the necessity to change recip-
ient at short notice (case 12). Table 1 details the donor livers;
9 were from DCD and 3 from DBD donors, with a median
age of 56 years (range, 24-67). Taking cold ischemic time to
end at commencement of normothermic perfusion, themedian
Donor Risk Index was 2.15 (range, 1.47-3.14).12,13
Perfusions
Normothermic ex situ liver perfusion began after amedian
cold storage period of 427 minutes (range, 222-877), and
livers underwent normothermic perfusion for a median of
284 minutes (range, 122-530) before being cold flushed for
implantation (Figure 2). The median total time from circula-
tory arrest in the donor to reperfusion in the recipient was
778 minutes (12 hours, 58 minutes), with a range from 564
to 1561 minutes (9 hours, 24 minutes to 26 hours, 1 minute).
In the first 6 cases, the mean arterial pO2 throughout
NESLiP was between 83 and 90 kPa (621-671 mm Hg),
whereas for the subsequent 6 cases, oxygenationwas reduced
and the mean arterial pO2 varied between 20 and 25 kPa
(153-187 mm Hg). Changes in perfusate lactate and glucose
concentrations are shown in Figures 3 and 4, respectively.
Livers cleared lactate at varying rates; case 6 had the slowest
rate of fall of lactate, whereas case 9, a liver with a traumatic
right lobe laceration and hematoma, had the most delayed
fall. Case 5, a liver with trauma to the right lobe, had a brisk
FIGURE 6. Relationship between perfusate ALT after 2 hours and the peak ALT posttransplantation. The peak ALT in the first 7 days
posttransplant is plotted against the perfusate ALTafter 2 hours. Note case 6 developed primary nonfunction. There was a significant correla-
tion between the values (correlation coefficient R2 = 0.56, p = 0.005). The dotted line is a linear regression plot constrained through the origin.
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initial fall in lactate, but thereafter, it remained slightly raised
throughout perfusion (around 2 mmol/L, 20 mg/dL).
Measurement of alanine transaminase (ALT) was performed
at 1 and 2 hours after start of NESLiP, and posttransplant
perfusate analysis provided additional measurements (Figure 5).
The relationship between perfusateALTconcentration at 2 hours
and peak ALT in the first 7 days posttransplant is shown
in Figure 6.
There were 2 technical problems during perfusions. One
related to occlusion of the biliary catheter in 3 cases, preventing
assessment of bile production (but without long term biliary
sequelae); bile production in the remaining 9 cases is shown
in Figure 7. The second related to occlusion of the hepatic
vein catheter shortly after beginning the perfusion in case
11; it was not used in the first 6 cases.
Recipients
The median age of recipients was 57 years (range, 46-65),
with a median Model for End-Stage Liver Disease (MELD)
score of 17 (range, 10-26) and a median United Kingdom
End-stage Liver Disease (UKELD) score of 55 (range, 49-64)
(Table 2).15,16 A UKELD greater than 49 corresponds to a
better survival posttransplant than remaining on the waiting
list. The first recipient had an uneventful course. Case 2
became hemodynamically unstable secondary to pulmonary
thromboemboli during the explant, and continued to have
further emboli in the postoperative period.
Case 6 had an unexpectedly difficult hepatectomy compli-
cated by coagulopathy and severe hemorrhage, with a 28-L
blood loss before implantation. The liver suffered primary
nonfunction, and the patient died despite urgent retrans-
plantation. Histology of the donor liver after explant showed
extensive necrosis, but it could not be determined whether
this preexisted at the time of implant or was a consequence
of the inotropes given postimplantation.
Five of the first 6 recipients suffered from postreperfusion
syndrome, and 4 developed sustained vasoplegia (see Table 2).
None of the subsequent 6 liver recipients, who received livers
treated with lower concentrations of oxygen, experienced
postreperfusion syndrome or vasoplegia.
Posttransplant Course
Eleven patients are alive at a median of 12 months
posttransplant (range, 9-24 months). Figure 8 shows the
postoperative biochemistry for the recipients. Three patients
(cases 3, 7, and 11) developed cholangiopathy demonstrated
on magnetic resonance cholangiopancreatography (MRCP)
(Table 3). All were DCD livers, with asystolic periods of 11
to 12 minutes, agonal periods of 12 to 30 minutes, and dura-
tions from treatment withdrawal in the donor to cold in situ
perfusion of 24 to 41minutes. Case 11 had a “15- to 30-minute”
cardiorespiratory arrest before admission. Cases 3 and
11 had evidence of complete destruction of periluminal and
deep peribiliary glands on a postreperfusion bile duct biopsy
suggesting preexisting biliary damage; case 7 did not have a
bile duct biopsy. Bile collected during NESLiP in cases 7
and 11 had a pH 6.9 and 7.2, respectively; the pH of bile in
case 3 was not measured.
Contemporaneous Cohort
Table 4 compares the outcomes of the NESLiP cases with a
comparable cohort of non-NESLiP cases. The outcomes for
the NESLiP cohort of declined livers are similar to those
nondeclined livers not subject to NESLiP.
DISCUSSION
Normothermic ex situ liver perfusion has been described in
2 settings, either used after cold storage for a period immedi-
ately before liver implantation or from the point of liver re-
covery from the donor until implantation.6,7,20,21 Here, we
describe a clinical series of NESLiP after a period of cold is-
chemia. NESLiP was used to permit assessment of declined
livers before transplantation and to stop further cold ische-
mic damage in marginal livers after visual inspection, for ex-
ample, to assess the degree of steatosis. Using this technique
we transplanted 12 livers, of which 10 had a Donor Risk
FIGURE 7. Cumulative bile production during normothermic ex situ liver perfusion. Bile production varied, and did not predict cholangiopathy
or viability. Note that cases 7 and 11 have evidence of ischemic cholangiopathy on MRCP even though they had some of the highest rates of
bile production; they also had the least alkali bile. Bile production could not be recorded in 3 livers due to occlusion of the biliary catheter. Bile
salts were not added to the perfusate.
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Index greater than 2.0.12 Five livers were associated with he-
modynamic instability in the recipients after reperfusion, pos-
sibly related to hyperoxia in the perfusate during NESLiP.
There was no hemodynamic disturbance in recipients of the
6 livers perfused at lower oxygen tensions. Whether the high
oxygen tensions were responsible for the incidence of
postreperfusion syndrome, or whether the nature of the
livers, or the duration of NESLiP, was responsible is not clear.
Previous investigators have described normothermic organ
perfusion using high perfusate oxygen tensions. Hosgood
and Nicholson22,23 report clinical results using a 95% O2
and 5%CO2mixture delivered to a single oxygenator for their
brief period of preimplant normothermic kidney perfusion
and have not reported postreperfusion syndrome or vasoplegia.
Similarly, high O2 partial pressures (275-650 mm Hg; 37-87
kPa) have been used in perfusion of livers in nonclinical re-
search.24-28 In all the liver perfusions cited above, the liver
was assessed ex vivo. In contrast, in a series of pig experi-
ments Schön et al29 transplanted livers after a 4-hour pe-
riod of NESLiP using a 95% O2/5% CO2 mixture to
oxygenate the arterial inflow, and mixed this oxygenated
bloodwith caval venous return to produce partially oxygenated
portal blood; they reported no adverse effects posttransplant.
High concentrations of oxygen in tissues can result in for-
mation of ROS and reactive nitrogen species (RNS), and
these agents can mediate reperfusion injury and cause refrac-
tory vasoplegia, as well as damaging the endothelial glycoca-
lyx.30-32 There is an extensive literature about the effects of
hyperoxemia during cardiopulmonary bypass, particularly
during reperfusion of the heart, where it is associated with
impaired myocardial and lung perfusion after reperfusion,
phenomena that are believed to be linked to ROS and RNS
production.33-35 Similar concerns exist regarding hyperoxemia
during extracorporeal membrane oxygenation and during re-
suscitation of neonates.36,37 Hyperoxia has been shown to
be associated with severe hepatic reperfusion injury in a rabbit
model, whereas hypoxia caused minimal reperfusion injury38;
hypoxia before normoxic reperfusion has also been shown
to prevent ROS production and depletion of antioxidants
in cardiac surgery.39 Although we have no direct proof that
hyperoxia during perfusion resulted in ROS and RNS dam-
age to the livers we transplanted, or caused the subsequent
postreperfusion syndrome and vasoplegia, we consider the
higher liver protein carbonyl content and higher perfusate
syndecan levels in discarded livers subject to NESLiP under
hyperoxic conditions to be suggestive (Figs. S1 and S2, SDC,
FIGURE 8. Posttransplant biochemistry. A, Posttransplant ALT (normal range, <50 IU/L). The ALT fell to normal in all patients except case 6
(not shown). The highest ALTs were in the 2 cases with parenchymal lacerations at the time of donation (cases 5 and 9). B, Posttransplant al-
kaline phosphatase (ALP) (normal range, <135 IU/L). Cases 3, 4, and 7 have persistently raised ALP posttransplant. Intrahepatic biliary stric-
tures have been demonstrated by MRCP in cases 3, 7, and 11. Case 4 has a 6-cm hilar mass in conjunction with a persistently positive
EBV PCR; he also had an anastomotic biliary stricture dilated 300 days posttransplant, although the relationship of this to the hilar mass is un-
clear. C, Posttransplant prothrombin time. The prothrombin time was persistently raised in case 12 with no obvious cause or clinical conse-
quence. Case 2 was on warfarin for a prosthetic aortic valve, although postoperatively she was maintained initially on subcutaneous low
molecular weight heparin. D, Posttransplant bilirubin. The bilirubin is raised in those cases with cholangiopathy (3, 7, and 11).
© 2017 Wolters Kluwer Watson et al 1093
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http://links.lww.com/TP/B394).Moreover, by simply reducing
perfusate oxygenation, we have seen no further problems on
reperfusion in the recipient.
Postreperfusion syndrome and vasoplegia have not been
reported after normothermic perfusion of kidneys in the clinic.
Severe liver disease is associated with impaired vasoreactivity
and marked splanchnic vasodilatation,40 which may make
the liver recipient's circulation more sensitive to inflammatory
mediators associated with graft injury. In addition, the short
duration of preimplant kidney perfusion may mitigate the ef-
fect. The only 1 of the first 6 livers we transplanted not to be
overtly affected had the shortest exposure to NESLiP and the
lowest MELD and UKELD (14 and 50, respectively). In con-
trast, the worst vasoplegia was seen in the recipient with a
MELD of 25 and the longest exposure to NESLiP. Another
factormay relate to the perfusate's hematocrit.Most of the ox-
ygen in the perfusate is carried by red cells, with only a small
proportion dissolved in solution, even at high oxygen tensions.
It is possible that the low hematocrit used in normothermic
kidney perfusion is protective by reducing oxygen carriage,
with oxygen consumption being indicated by a very low venous
oxygen saturation.
It has been suggested that the severity of reoxygenation in-
jury in patients undergoing cardiopulmonary bypass for cya-
notic heart disease, and during resuscitation of neonates,
relates to depletion of endogenous antioxidants.37,41 Our se-
ries of declined grafts are predominantly from DCD donors
and more susceptible to reperfusion injury and depletion of
natural anti-oxidants, making these livers more susceptible
to reoxygenation, particularly in the presence of hyperoxia.
It is noteworthy that all 6 of the first cohort of livers were
DCD livers, in contrast to just 3 of the second cohort, possibly
contributing to the higher incidence in the first cohort.
Postreperfusion syndrome was not reported in the initial
pilot study of the Metra (OrganOx, Oxford, UK) NESLiP
device.6 In that study, the livers were placed on the machine
at the point of retrieval and suffered little cold ischemia. In
addition, the perfusate oxygen tension on Metra is typi-
cally between 90 and 150 mm Hg (12 and 20 kPa) (David
Nasralla, personal communication). The perfusate com-
position used in that study was similar to the Gelofusine based
perfusate we used.
We used a combination of parameters to assess the livers
during perfusion. Previous hepatocellular damage was
reflected in the perfusateALTat 2 hours, bywhich pointmost
enzyme washout had occurred. Lactate metabolism to glu-
cose or glycogen occurs predominantly in periportal hepato-
cytes,42 so disturbances in lactate metabolismwere considered
to represent periportal hepatocyte damage or ongoing lactate
production (eg, from poorly perfused parenchyma). Flushing
the liver with compound sodium lactate before NESLiP
provided a higher baseline lactate whose metabolism could
be followed.
Glycogenolysis is anATP-independent process that continues
during cold storage and is enhanced at reperfusion43,44 and
explains the raised perfusate glucose seen in many of the
NESLiP cases. Although a raised glucose is commonly observed
during NESLiP, a normal glucose might be a manifestation of
glycogen exhaustion and/or extensive lobular damage, or it
may signify minimal ischemia. Hence, although a raised per-
fusate glucose may be a marker of moderate ischemia, a nor-
mal glucose may paradoxically represent either minimal or
severe ischemic damage. This was seen in case 6, where the
glucose was normal, probably as a result of global lobular in-
jury rather than implying a good liver as first thought. To rule
out severe lobular injury in case 10, a glucose challenge was
given after which the glucose fell rapidly. The fall in glucose
observed is explained by glucose entry into the liver via the
insulin-independent GLUT2 transporter, and its subsequent
incorporation into glycogen (data not shown).
Hepatic regulation of acid-base balance depends upon the
differential metabolism of glutamine along the lobule.45 An
TABLE 4.
Outcomes of livers subject to NESLiP compared with a cohort of contemporaneous liver transplants
Hyperoxic NESLiP Normoxic NESLiP All NESLiP Comparator cohort
No. livers 6 6 12 24
Offer type: fast-track offers 1 2 3 4
Zonal offers 3 1 4 16
National offers 2 1 3 4
Research offers 0 2 2 0
Donor type: DBD 0 3 3 6
DCD 6 3 9 18
Donor age: median (range) 53 (24-62) 56 (39-67) 56 (24-67) 54 (22-72)
Time from withdrawal to cold perfusion for DCDs: median (range), min 34 (17-160) 30 (24-34) 31 (17-160) 22 (12-124)
Cold ischemic time: median (range), min 390 (222-445) 522 (389-877) 427 (222-877) 439 (333-720)
NESLiP duration: median (range), min 267 (132-491) 365 (122-530) 284 (122-530) —
Extracorporeal storage time: median (range), min 723 (564-1039) 984 (665-1561) 777 (564-1561) 439 (333-720)
US Donor Risk Index: median (range)12 2.1 (1.9-2.5) 2.5 (1.5 - 3.1) 2.1 (1.5-3.1) 2.2 (1.5-3.8)
UK Donor Liver Index: median (range)14 1.9 (1.4-2.3) 1.9 (1.0-2.5) 1.9 (0.0-2.5) 1.8 (1.1-3.3)
Postreperfusion syndrome incidence 5/6 = 83% 0/6 = 0% — 6/24 = 25%
Vasoplegia incidence 4/6 = 67% 0/6 = 0% — 5/24 = 21%
Peak ALT in first 7 d: median (range), IU/L 1210 (329-4991) 780 (187-1743) 1069 (187-4991) 787 (155-2238)
Cholangiopathy (ignoring patient who died day 2) 1/5 = 20% 2/6 = 33% 3/11 = 27% 7/24 = 29%
Actual graft survival (median follow up. 12 mo; range, 9-24) 5/6 = 83% 5/6 = 83% 10/12 = 83% 21/24 = 88%
Actual patient survival (median follow up. 12 mo; range, 9-24) 5/6 = 83% 6/6 = 100% 11/12 = 92% 23/24 = 96%
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inability to regulate pH, with worsening acidosis, was con-
sidered to signify pan-lobular hepatocyte damage,46,47 and
it is noteworthy that case 6 had the greatest tendency to aci-
dosis during perfusion (data not shown).
Bile production has been suggested as a sensitivemarker of
liver viability during NESLiP.48-50 It is a complex process
dependent on the integrity of many facets of liver function.
Bile acids are secreted predominantly in zones 1 and 2,
whereas bicarbonate is secreted in zone 3.51 Viability of the
cholangiocytes will also influence the amount and quality
of bile production. Figure 7 shows varying patterns of bile
production. Case 10, the poorest bile producer, is a liver with
satisfactory function andminimal evidence of cholangiopathy,
whereas cases 7 and 11 are among the best producers of bile
that have developed clinically significant cholangiopathy.
Case 6, the liver suffering primary non function, also made
a reasonable amount of bile. It is unclear from our series
how much emphasis should be placed on the amount of bile
produced, but the ability to produce an alkali bile might be a
more significant marker of cholangiocyte integrity. Where
bile was produced and its pH measured, only the livers not
able to produce bile with a pH greater than 7.4 went on to
develop significant cholangiopathy.
The high incidence of cholangiopathy in this series is in
contrast to reports from researchers using cold machine per-
fusion, albeit of less marginal livers,52 but is similar to the
contemporaneous non-NESLiP cohort. The presence of se-
vere duct injury visible on duct biopsies before normothermic
perfusion in cases 3 and 11 suggests this might be a donor
phenomenon and not related to the perfusion technique.
In summary, our report shows that a period of normother-
mic perfusion before transplantation can allow biochemical
assessment of liver function and arrest of cold ischemia.
Hyperoxic perfusates were associated with postreperfusion
vasoplegia and hemodynamic instability, possibly as a conse-
quence of release of ROS and RNS, whereas lower perfusate
oxygen tensions were associated with an uneventful reper-
fusion, although the numbers are too small to confidently
make a causal association. We noted a high incidence of
cholangiopathy which was associated with an inability to
produce an alkali pH during NESLiP.
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